Sugi Predict

Sugi Predict / Compounds / SCHEMBL4609960

SCHEMBL4609960

SCHEMBL4609960

COc1ccccc1[C@@H](C)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.55
▸ CA2 P00918 4/20 0.55
▸ CA7 P43166 2/20 0.55
▸ CA9 Q16790 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ CA4 P22748 1/20 0.55
▸ CA14 Q9ULX7 1/20 0.55
▸ TP53 P04637 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ AGTR1 P30556 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ ACHE P22303 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ ENPP2 Q13822 1/20 0.46
▸ POLB P06746 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ IDO1 P14902 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14376164 1.00 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL3929903 1.00 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL30010698 1.00 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL343860 1.00 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL6180225 0.88 CA1 (0.43) CA1CA2CA7CA9CA12
SCHEMBL4440523 0.86 P2RX3 (0.42) AGTR1LMNACYP1A2ACHEKMT2A
SCHEMBL5667375 0.86 APP (0.46) CA1CA2CA7CA9CA12
SCHEMBL7259231 0.85 CA1 (0.60) CA1CA2CA7CA9CA12
SCHEMBL23084671 0.83 CA1 (0.57) CA1CA2CA7CA9CA12
SCHEMBL238441 0.83 CA1 (0.57) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174683-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-05-30 — — US disclosed
EP-4288437-A1 MAP4K1 INHIBITORS Bayer Aktiengesellschaft (DE) 2023-12-13 — — EP disclosed
US-20230285945-A1 CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2023-09-14 — — US disclosed
US-20230250093-A1 AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-08-10 — — US disclosed
WO-2022167627-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2022-08-11 — — WO disclosed
EP-3205656-A1 SOLID-SUPPORTED RUTHENIUM-DIAMINE COMPLEX, AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE COMPOUND Takasago International Corporation (JP) 2017-08-16 — — EP disclosed
US-9321045-B2 Catalyst and process for synthesising the same THE UNIVERSITY OF WARWICK (GB) 2016-04-26 — — US disclosed
US-9321045-B2 Catalyst and process for synthesising the same THE UNIVERSITY OF WARWICK (GB) 2016-04-26 — — US disclosed
US-9321045-B2 Catalyst and process for synthesising the same THE UNIVERSITY OF WARWICK (GB) 2016-04-26 — — US disclosed
US-20150290634-A1 Catalyst and Process for Synthesising the Same THE UNIVERSITY OF WARWICK (GB) 2015-10-15 — — US disclosed
EP-1308436-B1 CALCIUM RECEPTOR ANTAGONISTS JAPAN TOBACCO INC (JP) 2008-10-15 — — EP disclosed
CN-100398626-C Method for increasing helical twist rate, optically active compound, liquid crystal composition containing the same, and liquid crystal display element DAINIPPON INK & CHEMICALS (JP) 2008-07-02 — — CN disclosed
US-7211685-B2 Calcium receptor antagonists JAPAN TOBACCO INC. (JP) 2007-05-01 — — US disclosed
US-7211685-B2 Calcium receptor antagonists JAPAN TOBACCO INC. (JP) 2007-05-01 — — US disclosed
US-7211685-B2 Calcium receptor antagonists JAPAN TOBACCO INC. (JP) 2007-05-01 — — US disclosed
US-6916956-B2 Calcium receptor antagonist JAPAN TOBACCO, INC. (JP) 2005-07-12 — — US disclosed
US-20050107448-A1 Calcium receptor antagonists JAPAN TABACCO INC. 2005-05-19 — — US disclosed
CN-1495246-A Method for increasing helical twist rate, optically active compound, liquid crystal composition containing the same, and liquid crystal display element 大日本油墨化学工业株式会社 2004-05-12 — — CN disclosed
US-20040006130-A1 Calcium receptor antagonist JAPAN TOBACCO INC (JP) 2004-01-08 — — US disclosed
EP-1308436-A1 CALCIUM RECEPTOR ANTAGONISTS JAPAN TOBACCO INC. (JP) 2003-05-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290634-A1 Catalyst and Process for Synthesising the Same CBR3, SPR, RNF5 CA1 4151/4885CA2 3693/4885CA7 1183/4885
US-20240174683-A1 MAP4K1 INHIBITORS MAP3K4, MAP4K4, MAP4K1 CA1 4425/4885CA2 4104/4885CA7 4823/4885
US-20230285945-A1 CATALYST CONTAINING ACTIVATED CARBON ADSORBED WITH RUTHENIUM COMPLEX, AND METHOD FOR PRODUCING REDUCTION PRODUCT USING SAME RRS1, POR, SCO2 CA1 400/4885CA2 244/4885CA7 158/4885
US-20230250093-A1 AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS LPAR1, LPAR2, LPAR3 CA1 3899/4885CA2 2771/4885CA7 3751/4885
US-20050107448-A1 Calcium receptor antagonists CASR, CALCR, CALCRL CA1 331/4885CA2 75/4885CA7 561/4885
US-20040006130-A1 Calcium receptor antagonist CALCRL, CASR, CALCR CA1 255/4885CA2 53/4885CA7 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.